June 19, 2018

FDA Acceptance of IND to advance Phase III Clinical Trial COMPETE with Solucin® for Treatment of GEP-NET in the U.S.

Recruitment in the U.S. for the COMPETE trial to begin shortly. Solucin® studied as a first-line therapy. Exclusively-produced nephroprotective amino acid solution administered.

Full releases >>

June 05, 2018

ITM announces appointment of Philip E. Harris as new Chief Medical Officer

ITM Isotopen Technologien München AG (ITM), a specialized radiopharmaceutical company, today announced the appointment of Philip E. Harris, BSc MB BCh PhD FRCP FRCB, to the position of Chief Medical Officer (CMO), starting on...

Full releases >>

May 25, 2018

Marketing Authorization for TOCscan® (68Ga-Edotreotide) in Germany, Austria and France

ITM receives marketing authorization for a ready-to-use radiopharmaceutical in 3 European countries. TOCscan® will be the companion diagnostic in ITM´s theranostic approach for the treatment of Neuroendocrine Tumors.

Full releases >>

May 17, 2018

ITM Isotopen Technologien München AG chosen as a 2018 Red Herring Top 100 Europe Winner

Acknowledgement of ITM’s success in bringing a new promising therapy in Precision Oncology to market and to the patients

Full releases >>

May 02, 2018

ITM Isotopen Technologien München AG unterzeichnet Charta der Vielfalt

Mit der Unterstützung der Initiative „Diversity als Chance – die Charta der Vielfalt der Unternehmen in Deutschland“ setzt ITM Isotopen Technologien München AG ein wichtiges Zeichen für die Anerkennung von Vielfalt in der...

Full releases >>

February 26, 2018

Endocyte and ITM announce Supply Agreement for No-Carrier-Added Lutetium for the Phase 3 VISION Trial

Endocyte, Inc., and ITM Isotopen Technologien München AG (ITM) today announced a supply agreement under which ITM will supply to Endocyte the medical radioisotope no-carrier-added (n.c.a.) Lutetium (177Lu), EndolucinBeta®, to...

Full releases >>

December 06, 2017

First gastroenteropancreatic-neuroendocrine tumor (GEP-NET) patient in Europe for the COMPETE phase III clinical trial with n.c.a. 177Lu-Edotreotide (Solucin®)

First Patient enrolled in Europe for the clinical study COMPETE at the University Hospital Marburg, Germany. COMPETE to investigate a broad indication with non-functional GE-NET /functional or nonfunctional P-NET. Targeted...

Full releases >>